Biology is becoming engineerable

we are investing in a future where bioengineering has industrial scale and speed, and today’s barely conceivable medicines are routine

We partner with innovators

building groundbreaking companies with the following characteristics

agnostic across all life-threatening diseases with objective, well-established approvable endpoints

modality agnostic wherever cutting-edge discovery tools are being used to develop multiple compounds

lead candidate has human PoC or can achieve it within the horizon of our first investment

stage-appropriate evidence of repeatable and scalable manufacturing

"*" indicates required fields